Skin Cancer | Topics

Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels
October 05, 2020

A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.

PD-1 antibody Induces Clinical Activity in Patients with Locally Advanced Basal Cell Carcinoma
September 18, 2020

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

Personalized Cancer Vaccine Shows Long-Term Survival for Patients with High-Risk Melanoma
August 06, 2020

Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma
June 24, 2020

The FDA approved pembrolizumab for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Increases in Melanoma Risk in Patients Treated with Biologic Therapy Not Ruled Out
May 25, 2020

Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.

Tavo, Pembrolizumab Combo May Aid in Reducing Remissions in Advanced Melanoma
May 11, 2020

The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.

Improving Time from Diagnosis to Definitive Surgery in Black Patients with Melanoma
May 09, 2020

Researchers indicated that targeted approaches to improving time from diagnosis to definitive surgery for black patients are essential in reducing racial disparities in melanoma outcomes.

Cemiplimab Shows Promise for Patients with Advanced Basal Cell Carcinoma
May 06, 2020

Cemiplimab showed clinically meaningful and durable responses in this group of patients for whom there are no currently approved treatments.

Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen
April 29, 2020

Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.

Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise
March 26, 2020

Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.